Rm. 403, Integrated Science Research Center No.2,Peking University
2021-Present, Principal Investigator, Beijing Advanced Innovation Center for Genomics
2021-Present, Principal Investigator, Biomedical Pioneering Innovation Center, Peking University
2020-2021, Instructor, Harvard Medical School/Boston Children’s Hospital, Boston
2016-2020,Postdoctoral Research Fellow, Harvard Medical School/Boston Children’s Hospital, Boston
2010-2016, Ph.D. in Biochemistry and Molecular Biology, Peking University
2006-2010, B.S. in Biotechnology, Huazhong University of Science and Technology
The diversification of antibody is the hallmark of adaptive immunity, which can protect against antigen infection. The antibody diversification is from the RAG-mediated V(D)J recombination, activation-induced cytidine deaminase (AID)-initiated class switch recombination (CSR) and somatic hypermutation (SHM). While the off-targets of RAG- and AID-mediated recombination or mutation severely affect the genome stability and human health. Our group uses the combination of gene editing and genomics to systematically study the mechanism of antibody diversification, and the roles of dynamic chromatin structure in maintaining genomic stability, which also contribute to the understanding of immunological deficiency-related diseases and genome instability-related diseases.